Innoviva, Inc. - Quarter Report: 2018 June (Form 10-Q)

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2018

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                    to                   

 

Commission File Number: 000-30319

 

INNOVIVA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

2000 Sierra Point Parkway, Suite 500

Brisbane, CA 94005

(Address of Principal Executive Offices)

 

(650) 238-9600

(Registrant’s Telephone Number, Including Area Code)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

 

The number of shares of registrant’s common stock outstanding on July 19, 2018 was 101,507,745.

 

 

Table of Contents

 

TABLE OF CONTENTS

 

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017		3
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2018 and 2017		4
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2018 and 2017		5
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017		6
Notes to Condensed Consolidated Financial Statements		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		14
Item 3. Quantitative and Qualitative Disclosures About Market Risk		20
Item 4. Controls and Procedures		20
PART II. OTHER INFORMATION
Item 1. Legal Proceedings		21
Item 1A. Risk Factors		21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		21
Item 6. Exhibits		21
Signatures		22
Exhibits

 

2

Table of Contents

 

PART I — FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

INNOVIVA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

 

		June 30,			December 31,
		2018			2017
		(unaudited)			*
Assets
Current assets:
Cash and cash equivalents		$	87,226		$	73,336
Short-term marketable securities		20,316			55,739
Related party receivables from collaborative arrangements		70,542			70,540
Prepaid expenses and other current assets		576			754
Total current assets		178,660			200,369
Property and equipment, net		185			209
Capitalized fees paid to a related party, net		159,810			166,722
Other assets		37			37
Total assets		$	338,692		$	367,337
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable		$	58		$	601
Accrued personnel-related expenses		695			1,721
Accrued interest payable		5,115			5,920
Other accrued liabilities		909			1,500
Current portion of long-term debt		—			25,000
Total current liabilities		6,777			34,742
Long-term debt, net of current portion, discount and issuance costs		486,527			574,362
Other long-term liabilities		752			940
Commitments and contingencies
Stockholders’ deficit:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding		—			—
Common stock: $0.01 par value, 200,000 shares authorized, 101,657 and 102,046 shares issued as of June 30, 2018 and December 31, 2017, respectively		1,015			1,019
Treasury stock: 150 shares as of June 30, 2018 and December 31, 2017		(3,263		)	(3,263		)
Additional paid-in capital		1,259,443			1,258,151
Accumulated other comprehensive loss		(10		)	(18		)
Accumulated deficit		(1,414,541		)	(1,498,748		)
Total Innoviva stockholders’ deficit		(157,356		)	(242,859		)
Noncontrolling interest		1,992			152
Total stockholders’ deficit		(155,364		)	(242,707		)
Total liabilities and stockholders’ deficit		$	338,692		$	367,337

 

*Condensed consolidated balance sheet as of December 31, 2017 has been derived from audited consolidated financial statements.

 

See accompanying notes to condensed consolidated financial statements.

 

3

Table of Contents

 

INNOVIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2018			2017			2018			2017
Royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of $3,456 in the three months ended June 30, 2018 and 2017 and $6,912 in the six months ended June 30, 2018 and 2017		$	67,086		$	58,341		$	119,466		$	98,612
Revenue from collaborative arrangements from a related party		—			221			—			442
Total net revenue		67,086			58,562			119,466			99,054
Operating expenses:
Research and development		—			348			—			702
General and administrative		4,411			10,384			13,396			21,179
General and administrative - related party		—			—			2,700			—
Total operating expenses		4,411			10,732			16,096			21,881
Income from operations		62,675			47,830			103,370			77,173
Other income (expense), net		39			(786		)	(3,060		)	(739		)
Interest income		380			306			771			542
Interest expense		(6,478		)	(12,204		)	(14,135		)	(24,985		)
Net income		56,616			35,146			86,946			51,991
Net income attributable to noncontrolling interest		1,990			—			2,739			—
Net income attributable to Innoviva stockholders		$	54,626		$	35,146		$	84,207		$	51,991
Basic net income per share attributable to Innoviva stockholders		$	0.54		$	0.33		$	0.84		$	0.48
Diluted net income per share attributable to Innoviva stockholders		$	0.49		$	0.30		$	0.77		$	0.46
Shares used to compute Innoviva basic and diluted net income per share:
Shares used to compute basic net income per share		100,873			107,614			100,739			107,468
Shares used to compute diluted net income per share		113,399			120,463			113,483			120,317

 

See accompanying notes to condensed consolidated financial statements.

 

4

Table of Contents

 

INNOVIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

 

		Three Months Ended June 30,						Six Months Ended June 30,
		2018			2017			2018			2017
Net income		$	56,616		$	35,146		$	86,946		$	51,991
Unrealized income (loss) on marketable securities, net		12			1			8			(1		)
Comprehensive income		56,628			35,147			86,954			51,990
Comprehensive income attributable to noncontrolling interest		1,990			—			2,739			—
Comprehensive income attributable to Innoviva stockholders		$	54,638		$	35,147		$	84,215		$	51,990

 

See accompanying notes to condensed consolidated financial statements.

 

5

Table of Contents

 

INNOVIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

		Six Months Ended June 30,
		2018			2017
Cash flows from operating activities
Net income		$	86,946		$	51,991
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		6,936			6,991
Stock-based compensation		3,621			4,934
Amortization of debt discount and issuance costs		4,028			1,401
Loss on extinguishment of debt		3,137			830
Amortization of premium (discount) on short-term investments		(160		)	6
Amortization of lease guarantee		(162		)	(162		)
Changes in operating assets and liabilities:
Receivables from collaborative arrangements		(2		)	(14,949		)
Prepaid expenses and other current assets		178			124
Accounts payable		(543		)	149
Accrued personnel-related expenses and other accrued liabilities		(1,539		)	242
Accrued interest payable		(805		)	(725		)
Other long-term liabilities		4			10
Deferred revenue		—			(442		)
Net cash provided by operating activities		101,639			50,400
Cash flows from investing activities
Maturities of marketable securities		54,875			36,387
Purchases of marketable securities		(19,284		)	(11,969		)
Net cash provided by investing activities		35,591			24,418
Cash flows from financing activities
Repurchase of shares to satisfy tax withholding		(2,840		)	(847		)
Payments of principal on senior secured term loans		(120,000		)	—
Payments of cash dividends to stockholders		(55		)	(107		)
Proceeds from issuances of common stock, net		454			185
Payment of principal on non-recourse notes due 2029		—			(64,431		)
Distributions to noncontrolling interest		(899		)	—
Net cash used in financing activities		(123,340		)	(65,200		)
Net increase in cash and cash equivalents		13,890			9,618
Cash and cash equivalents at beginning of period		73,336			118,016
Cash and cash equivalents at end of period		$	87,226		$	127,634
Supplemental disclosure of cash flow information
Cash paid for interest		$	10,913		$	24,310

 

See accompanying notes to condensed consolidated financial statements.

 

6

Table of Contents

 

INNOVIVA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. Description of Operations and Summary of Significant Accounting Policies

 

Description of Operations

 

Innoviva, Inc. (referred to as “Innoviva”, the “Company”, or “we” and other similar pronouns) is focused on royalty management. Innoviva’s portfolio includes the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO®ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA®(umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is eligible to receive the associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to our consolidated variable interest entity, Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2018 or any other period.

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (“SEC”) on February 23, 2018 (“2017 Form 10-K”).

 

Variable Interest Entity

 

We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC.

 

Recently Issued Accounting Pronouncement Not Yet Adopted

 

In February 2016, the FASB issued ASU 2016-02, Leases, which supersedes the lease recognition requirements in ASC Topic 840, Leases. The standard requires an entity to recognize right-of-use assets and lease liabilities arising from a lease for both financing and operating leases in the consolidated balance sheets but recognize the impact on the consolidated statement of operations and cash flows in a similar manner under current GAAP. The standard also requires additional qualitative and quantitative disclosures. The standard is effective for us at the beginning January 1, 2019 and requires transition under a modified retrospective method. The most significant impact of the update to us is that we will be required to recognize a “right-of-use” asset and lease liability for the operating lease agreement that was not previously included on the balance sheet under the existing lease guidance. We anticipate that the treatment of the lease on our consolidated statement of operations and cash flows will not materially be affected by the adoption of the new standard.

 

2. Net Income Per Share

 

Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock

 

7

Table of Contents

 

equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the “2023 Notes”) using the if-converted method.

 

Our convertible senior notes due 2025 (the “2025 Notes”) are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of the 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share is computed using the treasury stock method. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market during the relevant periods was lower than the initial conversion price of $17.26 per share, there was no dilutive effect of the assumed conversion premium for the three and six months ended June 30, 2018.

 

The following table shows the computation of basic and diluted net income per share for the three and six months ended June 30, 2018 and 2017:

 

		Three Months Ended June 30,						Six Months Ended June 30,
(In thousands except per share data)		2018			2017			2018			2017
Numerator:
Net income attributable to Innoviva stockholders, basic		$	54,626		$	35,146		$	84,207		$	51,991
Add: interest expense on 2023 Notes		1,417			1,414			2,829			2,821
Net income attributable to Innoviva stockholders, diluted		$	56,043		$	36,560		$	87,036		$	54,812
Denominator:
Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders		100,873			107,614			100,739			107,468
Dilutive effect of 2023 Notes		12,189			12,189			12,189			12,189
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan		337			660			555			660
Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders		113,399			120,463			113,483			120,317
Net income per share attributable to Innoviva stockholders
Basic		$	0.54		$	0.33		$	0.84		$	0.48
Diluted		$	0.49		$	0.30		$	0.77		$	0.46

 

Anti-Dilutive Securities

 

The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti-dilutive:

 

		Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)		2018		2017		2018		2017
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan		1,633		2,019		1,562		2,541

 

3. Revenue Recognition and Collaborative Arrangements

 

Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. We recognize the royalty revenue on licensee net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned and reported to us. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.

 

8

Table of Contents

 

Net Revenue from Collaborative Arrangements

 

Net revenue recognized under our GSK Agreements was as follows:

 

		Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)		2018			2017			2018			2017
Royalties from a related party - RELVAR/BREO		$	57,515		$	54,645		$	103,675		$	93,334
Royalties from a related party - ANORO		10,656			7,152			19,380			12,190
Royalties from a related party - TRELEGY		2,371			—			3,323			—
Total royalties from a related party		70,542			61,797			126,378			105,524
Less: amortization of capitalized fees paid to a related party		(3,456		)	(3,456		)	(6,912		)	(6,912		)
Royalty revenue		67,086			58,341			119,466			98,612
Strategic alliance - MABA program license		—			221			—			442
Total net revenue from GSK		$	67,086		$	58,562		$	119,466		$	99,054

 

4. Available-for-Sale Securities and Fair Value Measurements

 

Available-for-Sale Securities

 

The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:

 

		June 30, 2018
(In thousands)		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Estimated Fair Value
U.S. corporate notes		$	3,879		$	—		$	(10	)	$	3,869
U.S. commercial paper		16,447			—			—			16,447
Money market funds		81,426			—			—			81,426
Total		$	101,752		$	—		$	(10	)	$	101,742

 

		December 31, 2017
(In thousands)		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Estimated Fair Value
U.S. government securities		$	9,943		$	—		$	(1	)	$	9,942
U.S. government agencies		9,987			—			(2		)	9,985
U.S. corporate notes		10,881			—			(15		)	10,866
U.S. commercial papers		29,945			—			—			29,945
Money market funds		61,971			—			—			61,971
Total		$	122,727		$	—		$	(18	)	$	122,709

 

As of June 30, 2018, all of the available-for-sale securities had contractual maturities within one year and the weighted average maturity of marketable securities was approximately three months.

 

9

Table of Contents

 

Fair Value Measurements

 

Our available-for-sale securities are measured at fair value on a recurring basis and our debt is carried at the amortized cost basis. The estimated fair values were as follows:

 

		Estimated Fair Value Measurements as of June 30, 2018 Using:
Types of Instruments		Quoted Price in Active Markets for Identical Assets			Significant Other Observable Inputs			Significant Unobservable Inputs
(In thousands)		Level 1			Level 2			Level 3			Total
Assets
U.S. corporate notes		$	—		$	3,869		$	—		$	3,869
U.S. commercial paper		—			16,447			—			16,447
Money market funds		81,426			—			—			81,426
Total assets measured at estimated fair value		$	81,426		$	20,316		$	—		$	101,742
Liabilities
Term B Loan		$	—		$	123,750		$	—		$	123,750
2023 Notes		—			226,525			—			226,525
2025 Notes		—			202,146			—			202,146
Total fair value of liabilities		$	—		$	552,421		$	—		$	552,421

 

		Estimated Fair Value Measurements as of December 31, 2017 Using:
Types of Instruments		Quoted Price in Active Markets for Identical Assets			Significant Other Observable Inputs			Significant Unobservable Inputs
(In thousands)		Level 1			Level 2			Level 3			Total
Assets
U.S. government securities		$	—		$	9,942		$	—		$	9,942
U.S. government agencies		—			9,985			—			9,985
U.S. corporate notes		—			10,866			—			10,866
U.S. commercial papers		—			29,945			—			29,945
Money market funds		61,971			—			—			61,971
Total assets measured at estimated fair value		$	61,971		$	60,738		$	—		$	122,709
Liabilities
Term B Loan		$	—		$	243,750		$	—		$	243,750
2023 Notes		—			241,259			—			241,259
2025 Notes		—			205,975			—			205,975
Total fair value of liabilities		$	—		$	690,984		$	—		$	690,984

 

The fair value of our marketable securities classified within Level 2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data, including market research publications.

 

The fair value of our 2023 Notes and of our 2025 Notes is based on recent trading prices of the instruments. The carrying amount of our initial senior secured term loan (the “Term B Loan”) before deducting debt issuance costs approximates fair value as the loan carries a variable interest rate that is tied to the LIBOR rate plus an applicable spread.

 

10

Table of Contents

 

5. Stock-Based Compensation

 

Market-Based RSAs and RSUs

 

2016 Market-Based RSAs and RSUs

 

On January 14, 2016, the Compensation Committee approved and granted 282,394 RSAs and 46,294 RSUs to senior management. These awards include a market condition based on Total Shareholder Return (“TSR”) and a service condition that requires continued employment, collectively the “Performance Measures I”. The vesting percentages of these awards are calculated based on the two-year TSR with a catch-up provision opportunity measured on January 13, 2019 for RSAs and on September 30, 2018 for RSUs. Two-thirds of amounts earned at the end of year two would vest and be distributed on February 20, 2018, while the final one-third earned after two years as well as the catch-up amount earned will vest and be distributed on February 20, 2019 for RSAs and November 20, 2018 for RSUs. The actual payout of shares may range from a minimum of zero shares to a maximum of 328,688 shares granted upon the actual performance against the Performance Measures I. The grant date fair value of these awards was determined using a Monte Carlo valuation model. The aggregate value of $2.0 million is recognized as compensation expense over the implied service period and will not be reversed if the market condition is not met, but with the exception of such person’s continued employment with the Company.

 

In February 2018, the Compensation Committee certified the maximum achievement of the TSR as of the first measurement date, January 12, 2018. 69,440 RSAs and 30,862 RSUs representing two-thirds of the amounts were released on February 20, 2018, and the remaining 34,720 RSAs and 15,432 RSUs will vest on February 20, 2019 subject to each eligible person’s continued employment with the Company. Additionally, in connection with certain members of senior management’s separation from the Company in early February 2018, the Board agreed to accelerate the vesting and distribution of an aggregate of 118,821 RSAs to these members of senior management. The remaining 59,411 RSAs for these members of senior management were forfeited. As a net result of the vesting acceleration of the RSAs and the forfeiture of those unvested RSAs, an additional $0.7 million compensation expense was recognized during the three months ended March 31, 2018.

 

2017 Market-Based RSAs and RSUs

 

On January 17, 2017, the Compensation Committee approved and granted 353,508 RSAs and 53,360 RSUs to senior management. These awards include a market condition based on the TSR of Innoviva’s common stock as compared to the TSR of NASDAQ Biotechnology Index (“Index”) and a service condition that requires continued employment, collectively the “Performance Measures II”. The vesting percentages of these awards are calculated based on the two-year performance period with a catch-up provision opportunity measured on December 31, 2019 for RSAs and on September 30, 2019 for RSUs. Two-thirds of amounts earned at the end of year two will vest and be distributed on February 20, 2019, while the final one-third earned after two years as well as the catch-up amount earned will vest and be distributed on February 20, 2020 for RSAs and November 20, 2019 for RSUs. The actual payout of shares may range from a minimum of zero shares to a maximum of 406,868 shares granted upon the actual performance against the Performance Measures II. The grant date fair value of these awards is determined using a Monte Carlo valuation model. The aggregate value of $3.2 million is recognized as compensation expense over the implied service period and will not be reversed if the market condition is not met, but with the exception of such person’s continued employment with the Company.

 

In connection with certain members of senior management’s separation from the Company mentioned above, an aggregate of 233,448 RSAs for these members of senior management were forfeited, and $0.8 million of previously recognized compensation expense was reversed during the three months ended March 31, 2018.

 

2018 Market-Based RSAs and RSUs

 

On March 2, 2018, the Compensation Committee approved and granted 111,668 RSAs and 49,630 RSUs to senior management. These awards include a market condition based on the TSR of Innoviva’s common stock over a three-year performance period from the date of grant for the RSAs and from the date of grant until September 30, 2020 for RSUs, and a service condition that requires continued employment, collectively the “Performance Measures III”. The actual payout of shares may range from a minimum of zero shares to a maximum of 161,298 shares granted upon the actual performance against the Performance Measures III. The grant date fair value of these awards was determined using a Monte Carlo valuation model. The aggregate value of $1.7 million is recognized as compensation expense over the implied service period and will not be reversed if the market condition is not met, but with the exception of such person’s continued employment with the Company.

 

11

Table of Contents

 

Stock-Based Compensation Expense

 

Stock-based compensation expense is included in the condensed consolidated statements of operations as follows:

 

		Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)		2018			2017			2018			2017
Research and development		$	—		$	175		$	—		$	353
General and administrative		1,452			2,252			3,621			4,581
Total stock-based compensation expense		$	1,452		$	2,427		$	3,621		$	4,934

 

As of June 30, 2018, unrecognized stock-based compensation cost, including performance-contingent RSAs for which the performance milestones were determined to be probable of achievement, was as follows:

 

(In thousands)		Unrecognized Compensation Cost
Stock options		$	19
RSUs		2,096
RSAs		3,521
Market-based RSUs		627
Market-based RSAs		1,493
Total unrecognized compensation cost		$	7,756

 

6. Debt

 

Our debt consists of:

 

		June 30,			December 31,
(In thousands)		2018			2017
Term B Loan		$	123,750		$	243,750
2023 Notes		240,984			240,984
2025 Notes		192,500			192,500
Total debt		557,234			677,234
Unamortized debt discount and issuance costs		(70,707		)	(77,872		)
Current portion of Term B Loan		—			(25,000		)
Net long-term debt		$	486,527		$	574,362

 

Prepayment of Senior Secured Term Loans

 

On February 28, 2018, we paid down the principal balance of the Term B Loan by $120.0 million. With the prepayment, we incurred a loss on the extinguishment of debt of $3.1 million representing unamortized debt issuance costs. The loss on the extinguishment of debt is presented as part of other income (expense), net in our consolidated statements of operations. As of June 30, 2018, the outstanding principal balance of the Term B Loan was reduced to $123.8 million.

 

Convertible Senior Notes Due 2025

 

In accordance with accounting guidance for debt with conversion and other options, we separately account for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (“equity component”) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense using the effective interest method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.

 

12

Table of Contents

 

Our outstanding 2025 Notes balances as of June 30, 2018, consisted of the following:

 

(In thousands)
Liability component
Principal		$	192,500
Debt discount and issuance costs, net		(65,119		)
Net carrying amount		$	127,381
Equity component, net		$	65,361

 

In connection with the issuance of the 2025 Notes, we incurred approximately $5.4 million of debt issuance costs, which primarily consisted of placement, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total $5.4 million of debt issuance costs, $1.9 million were allocated to the equity component and recorded as a reduction to additional paid-in capital and $3.5 million were allocated to the liability component and recorded as a reduction to the carrying amount of the liability component on the consolidated balance sheet. The portion allocated to the liability component is amortized to interest expense over the expected life of the 2025 Notes using the effective interest method.

 

The following table sets forth total interest expense recognized related to the 2025 Notes for the three and six months ended June 30, 2018:

 

		Three months ended			Six months ended
(In thousands)		June 30, 2018			June 30, 2018
Contractual interest expense		$	1,203		$	2,393
Amortization of debt issuance costs		125			248
Amortization of debt discount		1,496			2,975
Total interest and amortization expense		$	2,824		$	5,616

 

Debt Maturities

 

The aggregate scheduled maturities of our long-term debt (consisting of our Term B Loan, 2023 Notes and 2025 Notes) as of June 30, 2018, are as follows:

 

(In thousands)
Years ending December 31:
2018 to 2021		$	—
2022		123,750
Thereafter		433,484
Total		$	557,234

 

7. Related Party Transaction

 

On February 12, 2018, the Company entered into an agreement with Sarissa Capital Management LP, and certain of its affiliates (collectively, the “Sarissa Group”) related to the Company’s 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”). The agreement provided for, among other things, the concurrent appointment of three designees of the Sarissa Group as members of the Company’s Board of Directors and an agreement to recommend and nominate a five-person slate of directors for election at the 2018 Annual Meeting composed of the three new directors and two current directors of the Company and partially reimburse the Sarissa Group $2.7 million for expenses, which reimbursement obligation relating to the 2018 Annual Meeting arose upon execution of the agreement. The Sarissa Group is considered to be a related party due to its representation on the Board of Directors.

 

8. Income Taxes

 

There was no income tax expense for the three and six months ended June 30, 2018. Should we continue to generate taxable income in 2018, we expect that the taxable income will be substantially offset by the utilization of net operating losses or other deferred tax assets, and potential release of valuation allowance. The difference between the consolidated effective income tax rate and the U.S. federal statutory rate is primarily attributable to a change in valuation allowance against net deferred tax assets.

 

13

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

The information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve substantial risks, uncertainties and assumptions. All statements contained herein that are not of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives, may be forward-looking statements. The words “anticipates,” “believes,” “could,” “designed,” “estimates,” “expects,” “goal,” “intends,” “may,” “objective,” “plans,” “projects,” “pursue,” “will,” “would” and similar expressions (including the negatives thereof) are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward-looking statements and the assumptions underlying our forward-looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and objectives disclosed in the forward-looking statements that we make. All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Important factors that we believe could cause actual results or events to differ materially from our forward-looking statements include, but are not limited to, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of the Company (including the Company’s growth strategy and corporate development initiatives beyond the existing respiratory portfolio); the timing, manner, amount and planned growth of anticipated potential capital returns to stockholders (including, without limitation, statements regarding the Company’s expectations of future purchases under its future share repurchase authorizations and future cash dividends); the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; projections of revenue, expenses and other financial items; and risks discussed in “Risk Factors” in Item 1A of Part I of our 2017 Form 10-K and Item 1A of Part II of our Quarterly Reports on Form 10-Q and below in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Item 2 of Part I. All forward-looking statements in this document are based on information available to us as of the date hereof and we assume no obligation to update any such forward-looking statements on account of new information, future events or otherwise, except as required by law.

 

We encourage you to read our consolidated financial statements contained in this Quarterly Report on Form 10-Q. We also encourage you to read Item 1A of Part I of our 2017 10-K and Item 1A of Part II of our Quarterly Reports on Form 10-Q entitled “Risk Factors,” which contain a more complete discussion of the risks and uncertainties associated with our business. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission (SEC) from time to time, including on Form 10-K, Form 10-Q and Form 8-K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

 

OVERVIEW

 

Executive Summary

 

Innoviva, Inc. (“Innoviva”, the “Company” or “we”) is focused on the management of royalty revenues from RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, we are entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO® ELLIPTA® which tier upward at a range from 6.5% to 10%. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 

Our company structure and organization are tailored to our focused activities of managing our respiratory assets with GSK, the commercial and developmental obligations associated with the GSK Agreements, intellectual property, licensing operations,

 

14

Table of Contents

 

business development activities and providing for certain essential reporting and management functions of a public company. As of June 30, 2018, we had ten employees. Our revenues consist of royalties from our respiratory partnership agreements with GSK.

 

Recent Highlights

 

·                  GSK Net Sales:

·                  Second quarter 2018 net sales of RELVAR®/BREO® ELLIPTA® by GSK were $383.3 million, up 5.3% from $364.3 million in the second quarter of 2017, with $208.6 million in net sales from the U.S. market and $174.7 million from non-U.S. markets.

·                  Second quarter 2018 net sales of ANORO® ELLIPTA® by GSK were $163.9 million, up 49.0% from $110.0 million in the second quarter of 2017, with $111.8 million net sales from the U.S. market and $52.1 million from non-U.S. markets.

·                  Second quarter 2018 net sales of TRELEGY® ELLIPTA®  by GSK were $36.5 million. TRELEGY® ELLIPTA® was approved in September 2017.

 

·                  Product Updates:

·                  GSK announced in April 2018 the expanded label indication in the U.S. for TRELEGY®  ELLIPTA® in patients with COPD.

 

Collaborative Arrangements with GSK

 

LABA Collaboration

 

In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease (“COPD”) and asthma. The collaboration has developed three combination products: (1) RELVAR®/BREO® ELLIPTA® (FF/VI) (BREO® ELLIPTA® is the proprietary name in the U.S. and Canada and RELVAR® ELLIPTA® is the proprietary name outside the U.S. and Canada), a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF), (2) ANORO® ELLIPTA® (UMEC/VI), a once-daily medicine combining a long-acting muscarinic antagonist (“LAMA”), umeclidinium bromide (UMEC), with a LABA, VI and (3) TRELEGY® ELLIPTA®, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA and LABA.

 

As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.

 

2004 Strategic Alliance

 

In March 2004, we entered into the Strategic Alliance Agreement with GSK where GSK received an option to license exclusive development and commercialization rights to product candidates from certain of our discovery programs on pre-determined terms and on an exclusive, worldwide basis. In 2005, GSK licensed our MABA program for the treatment of COPD, and in October 2011, we and GSK expanded the MABA program by adding six additional Innoviva-discovered preclinical MABA compounds (the “Additional MABAs”). The development program has been funded in full by GSK and is in Phase II clinical studies stage. GSK is in the process of determining next steps for the program. For a detailed discussion of our alliance with GSK, see Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 23, 2018 (“2017 Form 10-K”).

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

15

Table of Contents

 

Revenue recognition

 

In May 2014, the FASB issued a new comprehensive revenue recognition standard, ASC 606. We adopted this standard on January 1, 2018 on a modified prospective basis. Under the new guidance, revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied.

 

The adoption of ASC 606 did not have a material impact on our consolidated financial statements as we do not have any unrecognized transaction price, other than sales-based royalty revenue, or any remaining performance obligations under our collaboration agreements. We continue to recognize the royalty revenue on licensee net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned and reported to us. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.

 

Income tax valuation allowance

 

As of December 31, 2017, we had federal net operating loss carryforwards of approximately $1.0 billion and federal research and development tax credit carryforwards of approximately $45.2 million.  As of June 30, 2018, the Company continues to maintain a full valuation allowance on its gross deferred taxes.  In assessing whether a valuation allowance is required against the deferred tax assets, the Company has considered the positive and negative evidence as well as sources of taxable income in assessing the realizability of the deferred tax assets. Realization of the deferred tax assets is dependent on future taxable income.  We have considered our 3-year cumulative income position as well as strategic options available to the Company that may raise uncertainty regarding continued profitability.  Provided that Innoviva continues to generate profits in future quarters and also narrows its strategic options to exclude those that raise uncertainty regarding future profitability, it is reasonably possible that the valuation allowance on the federal deferred tax assets could be removed in the near term.  This change in estimate on the realization of the deferred tax asset could result in an income tax benefit of approximately $0.2 billion in the period of change.

 

Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code Section 382. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.  The Company conducted a Section 382 analysis through December 31, 2016 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of the net operating loss or credit carryforwards are expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo another ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended.

 

There were no other significant changes to our critical accounting policies and estimates. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 23, 2018 provides a more complete discussion of our critical accounting policies and estimates.

 

16

Table of Contents

 

Results of Operations

 

Net Revenue

 

Total net revenue, as compared to the prior year period, was as follows:

 

		Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
(In thousands)		2018			2017			$			%		2018			2017			$			%
Royalties from a related party - RELVAR/BREO		$	57,515		$	54,645		$	2,870		5	%	$	103,675		$	93,334		$	10,341		11	%
Royalties from a related party - ANORO		10,656			7,152			3,504			49	%	19,380			12,190			7,190			59	%
Royalties from a related party - TRELEGY		2,371			—			2,371			*		3,323			—			3,323			*
Total royalties from a related party		70,542			61,797			8,745			14	%	126,378			105,524			20,854			20	%
Less: amortization of capitalized fees paid to a related party		(3,456		)	(3,456		)	—			—		(6,912		)	(6,912		)	—			—
Royalty revenue		67,086			58,341			8,745			15	%	119,466			98,612			20,854			21	%
Strategic alliance - MABA program license		—			221			(221		)	(100	)%	—			442			(442		)	(100	)%
Total net revenue from GSK		$	67,086		$	58,562		$	8,524		15	%	$	119,466		$	99,054		$	20,412		21	%

 

*Not meaningful

 

Total net revenue increased to $67.1 million and $119.5 million for the three and six months ended June 30, 2018, compared to $58.6 million and $99.1 million, respectively, for the same periods a year ago primarily due to the growth in prescriptions and market share quarter over quarter for both RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, and initiation of sales by GSK of TRELEGY® ELLIPTA® in the fourth quarter of 2017.

 

Research & Development

 

We did not incur research and development expenses during the three and six months ended June 30, 2018. For the three and six months ended June 30, 2017, we incurred $0.3 million and $0.7 million, respectively, in research and development activities related to the late-stage partnered respiratory assets with GSK.

 

General & Administrative

 

General and administrative expenses, as compared to the prior year period, were as follows:

 

		Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
(In thousands)		2018			2017			$			%		2018			2017			$			%
General and administrative expenses		$	4,411		$	10,384		$	(5,973	)	(58	)%	$	13,396		$	21,179		$	(7,783	)	(37	)%
General and administrative expenses - related party		—			—			—			—		2,700			—			2,700			—

 

General and administrative expenses for the three months ended June 30, 2018 were $4.4 million compared with $10.4 million in the three months ended June 30, 2017, a decrease of $6.0 million. The amount for the three months ended June 30, 2017 included $4.3 million of proxy contest and associated litigation costs. The rest of the decrease in general and administrative expenses in the three months ended June 30, 2018 is mainly attributable to lower personnel-related expenses, including stock-based compensation expenses, as a result of lower headcount.

 

General and administrative expenses for the six months ended June 30, 2018 were $13.4 million compared with $21.2 million in the six months ended June 30, 2017, a decrease of $7.8 million. The amount for the six months ended June 30, 2017 included $8.5 million of proxy contest and associated litigation costs. General and administrative expenses for the six months ended June 30, 2018 included $3.2 million cash severance payments in connection with certain members of senior management’s separation from the Company and payment of $2.7 million to Sarissa to partially reimburse expenses pursuant to a settlement agreement in February 2018. The rest of the decrease in general and administrative expenses in the six months ended June 30, 2018 is mainly attributable to lower personnel-related expenses, including stock-based compensation expenses, as a result of lower headcount.

 

17